JG
TNGX icon

Joel Greenblatt’s Tango Therapeutics TNGX Stock Holding History

Joel Greenblatt’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,137
Closed -$400K – 1889
2026
Q1 		$400K Buy
+19,137
New +$266K ﹤0.01% 1540

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Joel Greenblatt's TNGX Position: Q2 2026 in Review

Joel Greenblatt sold out of Tango Therapeutics (TNGX) in Q2 2026, closing a stake of 19,137 shares — an estimated $400K sold.

Joel Greenblatt first reported a position in TNGX in Q1 2026 and held it in 1 quarter. The position peaked at $400K in Q1 2026. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Joel Greenblatt reported no remaining Tango Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Joel Greenblatt sold 19,137 Tango Therapeutics shares in Q2 2026, an estimated $400K.
  • Joel Greenblatt first reported a position in Tango Therapeutics in Q1 2026 and held it in 1 quarter.
  • Joel Greenblatt's Tango Therapeutics position peaked at $400K in Q1 2026.
  • 246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.